Objective: DNA damage response (DDR) deficiency has emerged as a prominent
determinant of tumor immunogenicity. This study aimed to construct a DDR-related immune …

Background The DNA damage repair (DDR) pathway is one of the pathways of tumor
pathogenesis, but its relationship with the immunophenotype has not been clarified in colon …

3035 Background: We previously described a molecular subtype of tumors that presents an
innate immune response to intrinsic DNA damage. The associated gene expression pattern …

Objective: Immune checkpoint inhibitors (ICIs) have achieved remarkable results in cancer
treatments. However, there is no effective predictive biomarker for gastrointestinal (GI) …

As our understanding of the mechanisms of cancer treatment has increased, a growing
number of studies demonstrate pathways through which DNA damage repair (DDR) affects …

Recently several studies have demonstrated the implications of mutations in DNA damage
response (DDR) pathways for immune checkpoint blockade (ICB) treatment. However …

Background The development of immune checkpoint blockade (ICB) has changed the way
we treat various cancers. While ICB produces durable survival benefits in a number of …

A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

DNA damage repair (DDR) is critical in maintaining normal cellular function and genome
integrity and is associated with cancer risk, progression, and therapeutic response …

Targeting immune inhibitory checkpoint (IC) pathways have attracted great attention as a
promising strategy for treating gastrointestinal (GI) cancer. However, the therapeutic efficacy …